Table 3 Treatment-related adverse events
3-weekly docetaxel (n = 24) | 2-weekly docetaxel (n = 24) | |||
|---|---|---|---|---|
Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | |
Neutropenia | 7 (30%) | 4 (17%) | 5 (21%) | 0 |
Febrile neutropenia | .. | 3 (13%) | .. | 0 |
Anemia | 23 (96%) | 1 (4%) | 15 (63%) | 1 (4%) |
Thrombocytopenia | 4 (17%) | 2 (8%) | 2 (8%) | 0 |
Fatigue | 8 (33%) | 8 (33%) | 5 (21%) | 3 (13%) |
Peripheral neuropathy | 0 | 0 | 1 (4%) | 0 |
Allergic reaction | 0 | 0 | 1 (4%) | 0 |
Arthralgia | 8 (33%) | 0 | 6 (25%) | 0 |
Diarrhea | 6 (25%) | 0 | 7 (29%) | 0 |
Nausea | 4 (17%) | 1 (4%) | 5 (21%) | 0 |
AST elevation | 1 (4%) | 0 | 0 | 0 |
ALT elevation | 1 (4%) | 0 | 0 | 0 |